Pluri Inc.’s subsidiary, Pluri Biotech, has been granted a patent by the China National Intellectual Property Administration (CNIPA). Specifically, the patent is for Pluri Biotech’s proprietary 3D immune cell expansion and activation technology. China Patent Expands IP Portfolio With the approval, Pluri expands its intellectual property (IP) portfolio, joining patents in the U.S., Japan, Korea, Australia, and Israel. Pluri subsequently said growing its portfolio supports its strategy of gl...